Alexion Pharmaceuticals向SEC支付2140万美元以解决FCPA违法行为
总部位于康涅狄格州的Alexion Pharmaceuticals，Inc.同意支付2140万美元来解决SEC的指控
该公司贿赂土耳其和俄罗斯的外国官员违反了FCPA，
并且未在巴西和哥伦比亚的子公司中维护准确的账簿和记录。
SEC星期四在一项内部行政命令中指控Alexion违反了FCPA的账簿，记录和内部控制规定。
在不承认或否认SEC的调查结果的情况下，
Alexion同意支付350万美元的罚款，外加1420万美元的非法所得和约380万美元的判决前利息。
The investigation started in 2015, according to the company’s earlier SEC filings.
In May this year, Alexion said it received a declination from the DOJ for the FCPA investigation.
In Turkey and Russia,
Alexion paid government officials and doctors at state-connected hospitals to promote use of its blood-disease drug, Soliris.
Alexion retained a consultant in Turkey from 2010 to 2015 with ties to health officials.
Alexion Turkey paid the consultant over $1.3 million for “consulting fees and purported expense reimbursements,” the SEC said.
Alexion employees in Turkey “received limited training regarding anti-bribery compliance,” according to the the SEC order.
In Russia,
Alexion paid doctors at government hospitals over $1 million from 2011 to 2015 to increase Soliris prescriptions.
Alexion Russia recorded the payments as “honoraria, educational expenses, business meeting expenses, and scientific research.”
The bribery resulted in Alexion being “unjustly enriched” by about $6.6 million in Turkey and $7.5 million in Russia, the SEC said.
The FCPA Blog